**Supplemental Table S1. NOS expression and its relationship with human tumor progression.**

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>Tumour cells</th>
<th>Vascula r endothelial cells</th>
<th>Stromal / immune cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>nNOS, eNOS, iNOS</td>
<td>(iNOS)</td>
<td>IHC, ISH, NOS activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head and neck</td>
<td>iNOS, eNOS</td>
<td>eNOS, iNOS</td>
<td>IHC, WB, NB, RT-PCR, ISH, NOS activity</td>
</tr>
<tr>
<td>Thyroid*</td>
<td>iNOS</td>
<td>(iNOS)</td>
<td>IHC, ISH</td>
</tr>
<tr>
<td>Lung</td>
<td>eNOS, nNOS, iNOS</td>
<td>eNOS, iNOS</td>
<td>IHC, WB, exhaled NO</td>
</tr>
<tr>
<td>Thyroid*</td>
<td>iNOS, eNOS, cNOS, iNOS</td>
<td>iNOS, cNOS</td>
<td>IHC, RT-PCR, exhaled NO</td>
</tr>
</tbody>
</table>

**References:**

1-6, 7-18, 19, 20, 21-24

© 2006 Nature Publishing Group
iNOS, eNOS, (nNOS)

IHC, WB, EPR, NOS activity

iNOS with VEGF expression, microvascular density, tumour size, grade, lymph node metastasis, and poor survival

Nitrotyrosine level with VEGF-C expression, lymph node metastasis, and poor survival

eNOS/nNOS not with microvascular density or tumour size

eNOS negatively with grade and lymph node status

eNOS/iNOS not with tumour size or degree of differentiation

iNOS with apoptosis and inversely with tumour cell proliferation and tumour size

iNOS not with p53 and VEGF expression

eNOS with differentiation and negatively with serosal invasion

iNOS not with microvascular density

Pancreas

Coton

Colon

Stomach

iNOS

IHC, RT-PCR

iNOS in Barrett's oesophagus, dysplasia and carcinomas

Oesophagus

© 2006 Nature Publishing Group
<table>
<thead>
<tr>
<th>Tissue</th>
<th>NOS Activity</th>
<th>IHC, RT-PCR, NOS Activity</th>
<th>NOS Expression and More</th>
<th>Liver*</th>
<th>Gallbladder*</th>
<th>Bladder†</th>
<th>Kidney‡</th>
<th>Prostate</th>
<th>Gynaecological cancer *</th>
<th>Prostate</th>
<th>Gynaecological cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>iNOS</td>
<td>IHC, RT-PCR</td>
<td>Expression, prolymph, met.</td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallbladder</td>
<td>iNOS</td>
<td>IHC, RT-PCR</td>
<td>Expression, prolymph, met.</td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bladder</td>
<td>iNOS</td>
<td>IHC, RT-PCR</td>
<td>Expression, prolymph, met.</td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>eNOS</td>
<td>IHC, RT-PCR</td>
<td>Expression, prolymph, met.</td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>iNOS</td>
<td>IHC, RT-PCR</td>
<td>Expression, prolymph, met.</td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gynaecological cancer</td>
<td>iNOS</td>
<td>IHC, RT-PCR</td>
<td>Expression, prolymph, met.</td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td>iNOS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Mesothelioma**

**iNOS**

IHC, RT-PCR

iNOS not with apoptosis or microvascular density

80.81

NOSs in Parenthesis were only occasionally or faintly detected.

*Data for eNOS and nNOS are not available. †Localised in nerve fibres.

**Abbreviations:** nitric oxide (NO), NO synthase (NOS), constitutive NOS (cNOS), endothelial NOS (eNOS), inducible NOS (iNOS), neuronal NOS (nNOS), IHC, immunohistochemistry (IHC), in situ hybridization (ISH), Northern blot (NB), Western blot (WB), reverse transcription polymerase chain reaction (RT-PCR), growth factor (VEGF), vascular endothelial growth factor (VEGF), HIF-1α, hypoxia-inducible factor 1α, MAPK, mitogen-activated protein kinase, PI3K, phosphoinositide 3-kinase, ERK, extracellular signal-regulated kinase, TNF-α, tumor necrosis factor alpha, NOS-I, NOS-II, NOS-III, anti-NOS, cNOS, eNOS.


